» Articles » PMID: 32951290

A Novel Low-grade Nasopharyngeal Adenocarcinoma Characterized by a GOLGB1-BRAF Fusion Gene

Overview
Date 2020 Sep 20
PMID 32951290
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Nasopharyngeal adenocarcinoma is a rare malignancy that is classified into conventional/surface- and salivary-types. Herein we report the case of a 52-year-old male who presented with a right nasopharyngeal mass and right-sided hearing loss. Diagnostic imaging revealed a circumscribed 1.7 cm mass centred in the right antero-lateral aspect of the nasopharynx. A biopsy showed a gland-forming neoplasm that was in continuity with the surface epithelium. The tumor exhibited a nested to micro-papillary architecture, with mild cytologic atypia. Immunohistochemistry demonstrated diffuse staining for CK7, SOX10, and p16; the abluminal layer was highlighted by CK5 and p63, while the luminal cells expressed CD117. The tumor was not amenable to subclassification and was diagnosed as a low-grade nasopharyngeal adenocarcinoma, not otherwise specified (NOS). Subsequent RNA sequencing was performed which identified a novel GOLGB1-BRAF fusion product. Based on its unique morphology and molecular findings, this is presumed to represent a novel subtype of nasopharyngeal adenocarcinoma. In addition to being of diagnostic relevance, this fusion may ultimately represent a potential therapeutic target.

Citing Articles

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib.

Kato H, Kano S, Yasui Y, Nojiri Y, Yoshimitsu M, Nakamura M Case Rep Oncol. 2023; 16(1):1007-1012.

PMID: 37900828 PMC: 10601785. DOI: 10.1159/000533822.


Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.

Loo S, Yates M, Yang S, Oesterreich S, Lee A, Wang X Genes Chromosomes Cancer. 2022; 61(5):261-273.

PMID: 35106856 PMC: 8930468. DOI: 10.1002/gcc.23029.

References
1.
Schramm Jr V, Imola M . Management of nasopharyngeal salivary gland malignancy. Laryngoscope. 2001; 111(9):1533-44. DOI: 10.1097/00005537-200109000-00009. View

2.
Naumann N, Schwaab J, Metzgeroth G, Jawhar M, Haferlach C, Gohring G . Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Genes Chromosomes Cancer. 2015; 54(12):762-70. DOI: 10.1002/gcc.22287. View

3.
Franchi A, Innocenti D, Palomba A, Miligi L, Paiar F, Franzese C . Low prevalence of K-RAS, EGF-R and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-EGFR treatments. Pathol Oncol Res. 2013; 20(3):571-9. DOI: 10.1007/s12253-013-9730-1. View

4.
Bishop J, Weinreb I, Swanson D, Westra W, Qureshi H, Sciubba J . Microsecretory Adenocarcinoma: A Novel Salivary Gland Tumor Characterized by a Recurrent MEF2C-SS18 Fusion. Am J Surg Pathol. 2019; 43(8):1023-1032. DOI: 10.1097/PAS.0000000000001273. View

5.
Ross J, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J . The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2015; 138(4):881-90. PMC: 5049644. DOI: 10.1002/ijc.29825. View